Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1

Citation
Mh. Poczatek et al., Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1, AM J PATH, 157(4), 2000, pp. 1353-1363
Citations number
56
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
AMERICAN JOURNAL OF PATHOLOGY
ISSN journal
00029440 → ACNP
Volume
157
Issue
4
Year of publication
2000
Pages
1353 - 1363
Database
ISI
SICI code
0002-9440(200010)157:4<1353:GSOTGF>2.0.ZU;2-5
Abstract
Glucose is a key factor in the development of diabetic complications, inclu ding diabetic nephropathy. The development of diabetic glomerulosclerosis i s dependent on the fibrogenic growth factor, transforming growth factor-bet a (TGF-beta), previously we showed that thrombospondin-l (TSP-1) activates latent TGF-beta both in vitro and in vivo. Activation occurs as the result of specific interactions of latent TGF-beta with TSP-I, which potentially a lter the conformation of latent TGF-beta. As glucose also up-regulates TSP- 1 expression, we hypothesized that the increased TGF-beta bioactivity obser ved in rat and human mesangial cells cultured with high glucose concentrati ons is the result of latent TGF-beta activation by autocrine TSP-1. Glucose -induced bioactivity of TGF-beta in mesangial cell cultures was reduced to basal levels by peptides from two different sequences that antagonize activ ation of latent TGF-beta by TSP, but not by the plasmin inhibitor. aprotini n. Furthermore, glucose-dependent stimulation of matrix protein synthesis w as inhibited by these antagonist peptides, These studies demonstrate that g lucose stimulation of TGF-beta activity and the resultant matrix protein sy nthesis are dependent on the action of autocrine TSP-1 to convert latent TG F-beta to its biologically active form. These data suggest that antagonists of TSP-dependent TGF-beta activation may be the basis of novel therapeutic approaches for ameliorating diabetic renal fibrosis.